WATERTOWN, Mass., Nov. 19, 2021 (GLOBE NEWSWIRE) – EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company engaged in the development and commercialization of therapeutics to help improve the lives of patients with severe eye disorders , today announced the closing of the previously announced public offering of 5,122,273 common shares, which included the full exercise by the underwriters of their option to purchase an additional 1,095,000 common shares, and warrants pre-funded subscription plans to purchase up to a total of 3,272,727 common shares. The common shares were sold at a public offering price of $ 13.75 per share, and the pre-funded warrants were sold at a purchase price of $ 13.74 per pre-funded warrant, for proceeds. total gross of approximately $ 115.4 million, before deducting subscription discounts. and commissions and other offering charges payable by EyePoint. All titles were sold by EyePoint.
Cowen and Guggenheim Securities acted as co-book managers for the offer. Cantor acted as the passive book manager for the offering.
EyePoint intends to use the net proceeds of the offering to advance EYP-1901 into and through Phase 2 clinical trials for wet AMD, DR and RVO, as well as to support its development initiatives. pipeline at an early stage, and for general business purposes.
The securities described above have been offered by the Company in accordance with a prior registration statement on Form S-3 (No. 333-258598) previously filed with the Securities and Exchange Commission (SEC) on August 6, 2021 and declared effective by the SEC on August 11, 2021.
The securities have been offered by means of a prospectus supplement and an accompanying prospectus relating to the offering which form part of the registration statement. A final prospectus supplement relating to and describing the terms of the offer was filed with the SEC on November 18, 2021 and is available on the SEC’s website at www.sec.gov. Copies of the Final Prospectus Supplement and accompanying prospectus relating to the offering can be obtained from Cowen and Company, LLC, c / o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department , by phone at (833) 297-2926, or by email at PostSaleManualRequests@broadridge.com, Guggenheim Securities, LLC Attention: Equity Syndicate Department, 330 Madison Avenue, New York, NY 10017 or by phone at (212) 518 -9544, or by email to GSEquityProspectusDelivery @ guggenheimpartners.com, or Cantor Fitzgerald & Co., Attn: Capital Markets, 499 Park Avenue, 4th floor, New York, NY 10022; Email: firstname.lastname@example.org.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities described in this document, and there will be no sale of such securities in any state or jurisdiction in which such offering, solicitation or sale would be illegal. prior to registration or qualification under the securities laws of any such state or jurisdiction.
About EyePoint Pharmaceuticals
EyePoint Pharmaceuticals (Nasdaq: EYPT) is a pharmaceutical company engaged in the development and commercialization of therapeutics to help improve the lives of patients with serious eye disorders. The Company’s pipeline leverages its proprietary DurasertÂ® technology for prolonged intraocular drug delivery, including EYP-1901, a potential half-yearly anti-intravitreal anti-VEGF therapy initially targeting age-related wet macular degeneration. The Company has two commercial products: YUTIQÂ®, for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, and DEXYCUÂ®, for the treatment of postoperative inflammation following eye surgery. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.
SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION ACT OF 1995: To the extent that the statements made in this press release deal with information which is not historical, they are forward-looking statements under the Private Securities Litigation Reform Act of 1995. These statements include: but not limited to statements regarding the use of the proceeds of the offering and other statements identified by words such as “will”, “potential”, “could “,” Can “,” believe “,” intend “,” continue “,” “plans”, “expects”, “anticipates”, “estimates”, “may”, other words of similar meaning or the use of future dates. Forward-looking statements, by their nature, deal with matters that are, to varying degrees, uncertain. Uncertainties and risks could cause EyePoint’s actual results to differ materially from those expressed or implied by EyePoint’s forward-looking statements. For EyePoint, this includes stock price volatility and financial market uncertainties, the continued impact of the COVID-19 pandemic on EyePoint’s business, the medical community and the global economy, and the impact general commercial and economic conditions. More detailed information on these and other factors that could affect EyePoint’s actual results are described in the documents filed by EyePoint with the SEC, including its annual report on Form 10-K for the year ended 31. December 2020, as revised or supplemented by its quarterly reports. on Form 10-Q and other documents filed with the SEC. All forward-looking statements contained in this press release speak only as of the date of this press release. EyePoint assumes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Green room communications